MEK Inhibitors in Combination with Immune Checkpoint Inhibition: Should we be Chasing Colorectal Cancer or the KRAS Mutant Cancer
Open Access
- 26 May 2017
- journal article
- Published by Peertechz Publications Private Limited in Global Journal of Cancer Therapy
- Vol. 3 (1), 030-031
- https://doi.org/10.17352/gjct.000019
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Targeting the KRAS Pathway in Non-Small Cell Lung CancerThe Oncologist, 2016
- Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).Journal of Clinical Oncology, 2016
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsClinical Cancer Research, 2016
- PD-1 blockade in tumors with mismatch-repair deficiencyCôlon & Rectum, 2015
- Microsatellite Instability Testing and Its Role in the Management of Colorectal CancerCurrent Treatment Options in Oncology, 2015
- Oncogenic KRAS signalling in pancreatic cancerBritish Journal of Cancer, 2014
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012